Immune Checkpoint Inhibitor-induced Polymyalgia Rheumatica. [Review]
No Thumbnail Available
All Authors
Liew, DFL.
Mackie, SL.
Tison, A.
Sattui, SE.
Yates, M.
Buchanan, RRC.
Owen, CE.
LTHT Author
Mackie, Sarah
LTHT Department
Rheumatology
NIHR Leeds Biomedical Research Centre
NIHR Leeds Biomedical Research Centre
Non Medic
Publication Date
2024
Item Type
Journal Article
Review
Review
Language
Subject
Subject Headings
Abstract
Polymyalgia rheumatica (PMR) immune-related adverse events (ICI-PMRs) represent a novel, distinct entity, despite many clinical, laboratory, and imaging similarities to classical PMR. Important questions remain in differentiating ICI-PMR from classical PMR, as well as other immune-related adverse events and PMR mimics. Despite this, ICI-PMR currently takes treatment cues from classical PMR, albeit with considerations relevant to cancer immunotherapy. Comparisons between ICI-PMR and classical PMR may provide further bidirectional insights, especially given that important questions remain unanswered about both diseases. The cause of classical PMR remains poorly understood, and ICI-PMR may represent a model of induced PMR, with important therapeutic implications.
Journal
Rheumatic Diseases Clinics of North America